Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Recommendation of “Hold” from Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been given a consensus rating of “Hold” by the seven research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $4.00.

A number of brokerages have issued reports on HOWL. Weiss Ratings lowered shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd.

Werewolf Therapeutics Trading Up 2.4%

HOWL opened at $0.97 on Friday. The stock has a 50-day moving average price of $0.51 and a 200-day moving average price of $0.60. Werewolf Therapeutics has a 12-month low of $0.27 and a 12-month high of $2.38. The stock has a market capitalization of $46.96 million, a P/E ratio of -1.27 and a beta of 0.51.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.36. The business had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $21.00 million. On average, equities research analysts predict that Werewolf Therapeutics will post -0.89 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the sale, the insider directly owned 303,719 shares of the company’s stock, valued at $106,301.65. This represents a 57.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Luke Evnin sold 107,429 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total transaction of $33,302.99. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,824,647 shares of company stock worth $670,677. Insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its stake in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after acquiring an additional 221,766 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $409,000. Finally, Citadel Advisors LLC purchased a new position in Werewolf Therapeutics in the 3rd quarter worth approximately $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.